컨듀이트 파마슈티컬스(CDT)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.17 (-9.08%), 시가총액 $0.01B, 52주 최저~최고 $0.39 ~ $9.35.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Phar
컨듀이트 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
컨듀이트 파마슈티컬스의 현재 주가는 $0.17 (-9.08%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
컨듀이트 파마슈티컬스의 시가총액은 약 $0.01B입니다.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is